Oramed Pharmaceuticals, Inc. (ORMP) Drug News Sparks Profit-Taking in the Options Pits

Oramed Pharmaceuticals, Inc. (NASDAQ:ORMP) surged higher out of the gate following upbeat data on its insulin drug, sparking possible profit-taking among call option traders

by Kirra Fedyszyn

Published on May 18, 2016 at 10:34 AM

Oramed Pharmaceuticals, Inc. (NASDAQ:ORMP) stock popped more than 16% out of the gate, and briefly traded above recent resistance at the round-number $10 level, following highly anticipated news on the company's oral insulin drug, ORMD-0801. The pharmaceutical firm announced this morning that the treatment met goals in a Phase II trial in patients with type 2 diabetes, and must now move on to a Phase III trial before being submitted for approval. However, the drug data -- expected to be potentially "transformative" -- may have already been priced in to ORMP shares, which have erased their gains to sit 1.1% lower at $8.93, and it looks like call options holders may have cashed out just in time.

As of yesterday, call open interest on ORMP was at an annual high. Most of the calls resided at the overhead May 10 strike. Today, ORMP calls are trading at 60 times the average intraday pace, and it looks like possible sell-to-close action occurred at the May 10 call within the first few minutes of trading, when the stock was briefly in double-digit territory -- and within a chip-shot of new annual highs.

However, bearish bets have picked up steam on Oramed Pharmaceuticals, Inc. (NASDAQ:ORMP), with put volume hitting an annual high yesterday. The stock's 10-day International Securities Exchange (ISE), Chicago Board Options Exchange (CBOE), and NASDAQ OMX PHLX (PHLX) put/call volume ratio shows 1.63 puts bought to open for each call during the past two weeks, to be precise. Plus, while the stock is currently seated on the short-sale restricted list, short interest account for more than two weeks' worth of trading, at ORMP's average daily volume. 

Sign up now for Schaeffer's Market Recap to get all the day's big stock movers, must-know technical levels, and top economic stories straight to your inbox.

A Schaeffer's exclusive!

The Expert's Guide

Access your FREE trading earning announcements before it's too late!


  
 

Partnercenter


NEW! Explore Schaeffer’s Partners' deals and get connected to top online brokerages with deals tailored exclusively for our readers.  Get answers to your questions regarding transfer fees, commission rates, programs and available discounts related to online trading services.

MORE | MARKETstories


Research Exposes Shortcut to Stock Market Wins
A simple way to stop picking losers, and start cashing in like Wall Street's elite.
Cannabis Stock Rally Cut Short after Downgrade
Aurora Cannabis did receive a price-target hike from Jefferies, though
Vaccines, China Trigger Roller Coaster Week for Stocks
Moderna's vaccine captured the attention of Wall Street
Research Exposes Shortcut to Stock Market Wins
A simple way to stop picking losers, and start cashing in like Wall Street's elite.